BACKGROUND: Radiofrequency ablation (RFA) is a relatively new treatment for unresectable hepatic tumors. The purpose of this analysis was to examine the frequency of complications and local recurrence associated with RFA. METHODS: Patients who underwent RFA of hepatic tumors with curative intent were included in this study. At laparotomy, RFA was performed using intraoperative ultrasound guidance. Computed tomography scans were obtained in the immediate postoperative period and every 3 to 6 months thereafter. RESULTS: Forty patients underwent RFA for 122 hepatic tumors. Thirty-one patients had metastatic lesions from colorectal cancer; 9 had other liver tumors. Complications occurred in 8 patients. With 9.5 months median follow-up, 6 patients had local recurrence of their ablated tumors. CONCLUSIONS: Our initial experience shows that RFA can effectively eradicate unresectable hepatic tumors. The rate and severity of complications appear acceptable. However, further study is necessary to assess long-term recurrence rates and effect on overall survival.
BACKGROUND: Radiofrequency ablation (RFA) is a relatively new treatment for unresectable hepatic tumors. The purpose of this analysis was to examine the frequency of complications and local recurrence associated with RFA. METHODS:Patients who underwent RFA of hepatic tumors with curative intent were included in this study. At laparotomy, RFA was performed using intraoperative ultrasound guidance. Computed tomography scans were obtained in the immediate postoperative period and every 3 to 6 months thereafter. RESULTS: Forty patients underwent RFA for 122 hepatic tumors. Thirty-one patients had metastatic lesions from colorectal cancer; 9 had other liver tumors. Complications occurred in 8 patients. With 9.5 months median follow-up, 6 patients had local recurrence of their ablated tumors. CONCLUSIONS: Our initial experience shows that RFA can effectively eradicate unresectable hepatic tumors. The rate and severity of complications appear acceptable. However, further study is necessary to assess long-term recurrence rates and effect on overall survival.
Authors: David M Cash; Michael I Miga; Sean C Glasgow; Benoit M Dawant; Logan W Clements; Zhujiang Cao; Robert L Galloway; William C Chapman Journal: J Gastrointest Surg Date: 2007-07 Impact factor: 3.452
Authors: John L Nosher; Inaya Ahmed; Akshar N Patel; Vyacheslav Gendel; Philip G Murillo; Rebecca Moss; Salma K Jabbour Journal: J Gastrointest Oncol Date: 2015-04
Authors: G Navarra; A Ayav; J-C Weber; S L Jensen; C Smadga; J P Nicholls; N A Habib; L R Jiao Journal: Int J Colorectal Dis Date: 2005-04-28 Impact factor: 2.571